FDA Proposes to Let NAC Be Sold as a Dietary Supplement: What Amazon Sellers Should Know
FDA proposed a rule that would let NAC be marketed as a dietary supplement. Comments close Jan. 19, 2027. What Amazon sellers should do now.
The Food and Drug Administration has proposed a rule that, if finalized, would allow products containing N-acetyl-L-cysteine (NAC) to be lawfully marketed as dietary supplements, provided those products are not otherwise in violation of the Federal Food, Drug, and Cosmetic Act. The proposal was published in the Federal Register on November 17, 2026.
This is a proposed rule, not a final one. NAC is still excluded from the legal definition of a dietary supplement today. FDA says it will continue its current enforcement discretion while the rulemaking proceeds. Comments are due by January 19, 2027.
Why NAC has been in a gray area
NAC is a form of the amino acid cysteine. It is sold both as an FDA-approved drug and, for many years, in products labeled as dietary supplements. In the proposed rule, FDA says NAC is a dietary ingredient, and that it is not a "new dietary ingredient," because NAC-containing supplements were advertised in the United States before October 15, 1994. A product can still fall outside the legal definition of a dietary supplement.
That is because of the drug-exclusion clause in section 201(ff)(3)(B) of the FD&C Act. If an article was approved as a new drug before it was marketed as a food or dietary supplement, products that include it are generally excluded, unless FDA issues a regulation after notice and comment finding that the article would be lawful under the Act. FDA says NAC (acetylcysteine) was approved as a new drug on September 14, 1963, under New Drug Application 013601, Mucomyst, and that it is not aware of evidence NAC was marketed as a food or dietary supplement before that date. On that basis, FDA has long taken the position that NAC-containing products cannot be dietary supplements.
In 2021, the Council for Responsible Nutrition and the Natural Products Association filed citizen petitions asking FDA to change that conclusion. NPA also asked FDA to start rulemaking if it would not change its position. On March 31, 2022, FDA denied the requests to declare that NAC is not excluded, and left open the rulemaking request.
In August 2022, FDA issued final guidance saying it intended to exercise temporary enforcement discretion for certain NAC-containing products labeled as dietary supplements. That policy applies only to products that would be lawfully marketed dietary supplements if NAC were not excluded, and that are not otherwise in violation of the FD&C Act. It does not apply to disease claims, or to products that are adulterated or misbranded for other reasons. The November 16, 2026 constituent update says FDA intends to continue that policy during this rulemaking.
What the proposed rule would change
FDA is proposing a new regulation at 21 CFR 190.1. NAC would be the first, and at the outset the only, ingredient listed. The Federal Register notice says this would be FDA's first use of its rulemaking authority under the exclusion clause in section 201(ff)(3)(B).
If the rule is finalized, NAC would no longer be excluded from the dietary supplement definition, and adding NAC to a dietary supplement would not be a prohibited act under section 301(ll) of the FD&C Act. A product that is or contains NAC, is labeled as a dietary supplement, and otherwise meets the definition would be regulated as a dietary supplement. FDA intends to withdraw the 2022 enforcement-discretion guidance. The rule would take effect immediately on publication of the final rule; that effective date is also a proposal, and FDA has asked for comment on it.
FDA's stated basis is a safety review of ingested NAC and a judgment that allowing supplement use is likely to have little, if any, impact on NAC drug development. That is FDA's assessment in a proposed rule. It is not a license to make disease claims, and it is not medical advice.
What the proposed rule would not change
The proposal would not, by itself, make a noncompliant product lawful. Products would still have to meet the rest of the dietary supplement definition and the usual rules, including current good manufacturing practice under 21 CFR part 111.
It would not authorize disease claims. A product intended to diagnose, cure, mitigate, treat, or prevent disease is a drug under the FD&C Act. The 2022 guidance already carved those products out of enforcement discretion. In the preamble, FDA also notes 2020 warning letters to companies that claimed to treat or prevent hangovers while labeling NAC products as dietary supplements.
It would not automatically clear any other ingredient caught by the same drug-exclusion clause. The proposed regulation lists only N-acetyl-L-cysteine and reserves space for other ingredients to be added later. Any later addition would require its own rulemaking. And the proposal is not in effect. Until FDA finalizes a rule, the legal exclusion remains, and sellers are still operating under temporary enforcement discretion.
How to comment, and by when
Electronic or written comments must be submitted by January 19, 2027. Regulations.gov will accept electronic comments until 11:59 p.m. Eastern Time at the end of that day. Late comments will not be considered.
Use Docket No. FDA-2025-N-2699. You can submit a comment through Regulations.gov, or send written comments to FDA's Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Electronic comments are posted, so do not include confidential business information unless you follow FDA's instructions for a confidential paper submission. If you are deciding whether to comment on your own products, talk to your regulatory counsel.
What it means for Amazon sellers
If you sell NAC on Amazon, the proposal does not require you to change your listing today, and it does not give you a new marketing claim. Until a final rule is published, treat the legal status as unchanged: NAC remains excluded, and FDA's enforcement discretion still applies only to products that would otherwise be lawful supplements and that do not make disease claims or otherwise violate the Act.
If the rule is finalized, qualifying NAC products would have a clearer legal path as dietary supplements. They would still have to comply with supplement labeling, manufacturing, and claims rules, and with Amazon's current dietary supplement category requirements and prohibited-claims policies in Seller Central. Amazon can still enforce its own listing rules.
Titles, bullet points, A+ content, backend search terms, and images all count. Do not claim that an NAC product diagnoses, cures, mitigates, treats, or prevents a disease, and do not treat FDA's proposal as permission to imply that the product is an approved drug or that FDA has approved your listing. If you are unsure whether a statement is a structure/function claim or a disease claim, talk to your regulatory counsel. Make sure the Amazon listing matches the physical label. See Brightview's supplement seller consulting page and Listing Compliance Checker.
A related proposal, H.R. 8370, is a separate bill in Congress. It has not become law and would not decide whether NAC is a lawful dietary ingredient. The Council for Responsible Nutrition welcomed FDA's NAC proposal but said it does not resolve broader drug-preclusion questions. CRN also reiterated support for H.R. 10336, the Dietary Supplement Innovation Act, introduced by Rep. Diana Harshbarger on September 10, 2026, and referred to the House Energy and Commerce Committee. That bill is not part of this rulemaking, and it is not law.
What to do now
- Do not change labels, Amazon claims, or product copy just because FDA has issued a proposal. The rule is not final.
- If you already sell NAC, review the listing and the physical label for disease claims and for mismatches. Stay inside the 2022 enforcement-discretion lane: products that would otherwise be lawful supplements, and that are not otherwise in violation of the FD&C Act.
- If you are considering a new NAC product, or want to comment on the proposal, talk to your regulatory counsel first. Comments are due by January 19, 2027, at 11:59 p.m. Eastern Time, under Docket No. FDA-2025-N-2699.
- Watch for a final rule or a withdrawal of the 2022 guidance. Brightview Strategies will post an update if the status changes.
If you want help reviewing NAC or other supplement listings, contact Brightview Strategies or call (843) 900-0526.
This post is for general information only and is not legal advice. You should consult qualified regulatory counsel about how FDA's proposal, the current enforcement-discretion policy, and any final rule would apply to your products and business.
Selling on Amazon?
Brightview Strategies runs listings, PPC, compliance, and account management for sellers of all kinds of products. First consultation is free.
Get in touchRelated posts
Amazon Will Delete Leftover Legacy Ads Reports on December 31: What to Export and How to Rebuild Them
Amazon will delete leftover legacy Ads reports on Dec. 31, 2026. The old pages go read-only Dec. 17. What to export and how to rebuild them.
H.R. 8370 Would Require a Public FDA Listing for Every US Supplement: What Amazon Sellers Should Know
H.R. 8370 would require every US supplement to be listed with FDA and a number on the label. The bill is not law. What Amazon sellers should do now.
Amazon Now Shows Estimated Lead Times for US FBA Shipments: How to Use Them This Holiday Season
Amazon is adding estimated receive and Prime-eligible lead times to US FBA shipments. What changed, what the numbers mean, and how to plan restocks around them.